Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC)

    Provides 5-year disease-free prognosis for localized and metastatic RCC.

    INSTRUCTIONS

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with RCC, localized or metastatic, particularly those being considered for clinical trial enrollment.

    • This score placed patients with local or metastatic renal cell carcinoma (mRCC) into mortality risk groups: low, intermediate/moderate, and high.
    • The derivation and numerous external validations have been chart reviews, though all find orderly progressions in 5-year survival based on group.
    • Prospective validation is eagerly awaited, and we know of no validations including substantial numbers of patients treated with modern targeted VEGF therapy.

    There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.

    Metastatic
    Localized
    I
    II
    III
    IV
    0
    ≥1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Amnon Zisman

    About the Creator

    Amnon Zisman, MD, is professor of urologic surgery at Sackler School of Medicine affiliated Tel Aviv University. He is currently head of urology department at Assaf Harofeh Medical Center. Dr. Zisman’s research focuses on increased accuracy of diagnosis and prognosis of RCC as well as novel treatment strategies in renal disease.

    To view Dr. Amnon Zisman's publications, visit PubMed

    Are you Dr. Amnon Zisman? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    About the Creator
    Dr. Amnon Zisman
    Are you Dr. Amnon Zisman?
    Also from MDCalc...
    You might be interested in...
    Guidelines
    Renal Mass and Localized Renal Cancer

    Guideline from AUA